Skip to main content

Table 1 Summary of study population characteristics at baseline (mITT population)

From: Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study

  All patients
(N = 8509)
Age, years, mean (SD) 64.7 (7.6)
Male, n (%) 5081 (59.7)
Treatment arm, n (%)
 BGF 320/18/9.6 µg 2137 (25.1)
 BGF 160/18/9.6 µg 2121 (24.9)
 GFF 18/9.6 µg 2120 (24.9)
 BFF 320/9.6 µg 2131 (25.0)
ICS use, n (%) 6846 (80.5)
Number of moderate or severe exacerbations in last year, median (range) 2 (0–12)
 1, n (%) 3699 (43.5)
  ≥ 2, n (%) 4810 (56.5)
Blood eosinophil count, mean × 109/L (SD) 196.4 (132.8)
Post-bronchodilator FEV1% predicted, mean % (SD) 43.4 (10.3)
  1. BFF Budesonide/formoterol, BGF Budesonide/glycopyrronium/formoterol, FEV1 Forced expiratory volume in 1 s, GFF Glycopyrronium/formoterol, ICS Inhaled corticosteroid, mITT Modified intent-to-treat, SD Standard deviation